Free Trial
NASDAQ:SONN

Sonnet BioTherapeutics Q3 2025 Earnings Report

Sonnet BioTherapeutics logo
$2.88 -0.10 (-3.36%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.90 +0.02 (+0.69%)
As of 08/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonnet BioTherapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.49
Beat/Miss
N/A
One Year Ago EPS
N/A

Sonnet BioTherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sonnet BioTherapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Sonnet BioTherapeutics Earnings Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
See More Sonnet BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonnet BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonnet BioTherapeutics and other key companies, straight to your email.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics (NASDAQ:SONN), a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

View Sonnet BioTherapeutics Profile

More Earnings Resources from MarketBeat